Discontinuation of Vioxx (multiple letters)

Lancet

Volumn 365, Issue 9453, 2005, Pages 23-28

  Kim, Peter S ^a   Reicin, Alise S ^a   Lièvre, Michel ^b   Abadie, Eric ^c   Garattini, Silvio ^d   Bertelé, Vittorio ^d   Nyberg, Jack ^e   McLean, Thomas R ^f   Boers, Maarten ^g   Jüni, Peter ^h,i   Reichenbach, Stephan ^h,i   Dieppe, Paul A ⁱ   Egger, Matthias ^h,i   Mitchell, Jane A ^j   Warner, Timothy D ^k   Nutt, David J ⁱ  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITÉ LYON 1   (France)

^c AFSSAPS   (France)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e SANOFI PASTEUR   (France)

^f 4104 S Forth St T   (United States)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ UNIVERSITY OF BRISTOL   (United Kingdom)

^j NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^k QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BENZODIAZEPINE; CELECOXIB; CHLORDIAZEPOXIDE; CYCLOOXYGENASE 2 INHIBITOR; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; ROFECOXIB; THALIDOMIDE; THIORIDAZINE; LACTONE; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFONE;

CARDIOTOXICITY; CLINICAL TRIAL; CONGENITAL MALFORMATION; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HEART INFARCTION; HEART PROTECTION; HUMAN; LETTER; PRIORITY JOURNAL; STROKE; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DRUG APPROVAL; EUROPEAN UNION; META ANALYSIS; NOTE; UNITED STATES; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE INHIBITORS; DRUG APPROVAL; EUROPEAN UNION; HUMANS; LACTONES; META-ANALYSIS; NAPROXEN; SULFONES; UNITED STATES; MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 19944427165     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)17652-6     Document Type: Letter

References (0)